PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1424453
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1424453
Global Acinetobacter Pneumonia Therapeutics Market, By Drug Class, By Route of Administration, By Geography
The global acinetobacter pneumonia therapeutics market size is expected to reach US$ 899.1 Mn by 2030, from US$ 614.6 Mn in 2023, exhibiting a CAGR of 5.6% during the forecast period.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023/2024: | US$ 614.6 Mn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023/2024 to 2030/2031 CAGR: | 5.60% | 2030/2031 Value Projection: | US$ 899.1 Mn |
Acinetobacter pneumonia is a severe type of pneumonia caused by the Acinetobacter species of bacteria. These bacteria are commonly found in soil and water. In recent times, there has been a steep rise in the number of cases of hospital-acquired pneumonia caused by multidrug-resistant Acinetobacter strains. Typically, it affects immunocompromised patients or those on mechanical ventilation in intensive care units. Antibiotic resistance has emerged as a major challenge in treating Acinetobacter pneumonia. Novel therapeutic approaches targeting this pathogen are the need of the hour.
Market Dynamics:
The global Acinetobacter pneumonia therapeutics market is driven by the growing prevalence of drug-resistant strains and increasing incidence of hospital-acquired or ventilator-associated pneumonia. According to the Centers for Disease Control and Prevention, Acinetobacter infections account for 8-10% of all hospital-acquired pneumonia cases in the U.S. every year. Moreover, the restricted antibacterial pipeline and lack of approved therapies specific to Acinetobacter pneumonia act as opportunities in the market. However, high development costs and regulatory hurdles associated with new drug approvals hamper the market growth. The market is influenced by factors such as increasing incidence of multidrug-resistant strains, advancements in diagnostic technologies, and the need for effective treatment options. Collaborations between pharmaceutical companies, research institutions, and healthcare providers play a crucial role in advancing therapeutic solutions. The evolving landscape of infectious diseases and the impact of the COVID-19 pandemic underscore the importance of sustained efforts to address Acinetobacter pneumonia through innovative therapeutic interventions and public health measures.
Key Features of the Study:
This report provides an in-depth analysis of the global acinetobacter pneumonia therapeutics market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global acinetobacter pneumonia therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc (GSK), AstraZeneca plc, Novartis AG, Johnson & Johnson, Sanofi S.A., Bayer AG, and Basilea Pharmaceutica
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global acinetobacter pneumonia therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acinetobacter pneumonia therapeutics market.
Detailed Segmentation:
- Global Acinetobacter Pneumonia Therapeutics Market, By Drug Class
- Cephalosporins
- Carbapenems
- Aminoglycosides
- Polymyxins
- Global Acinetobacter Pneumonia Therapeutics Market, By Route of Administration
- Oral
- Intravenous
- Others
- Global Acinetobacter Pneumonia Therapeutics Market, By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Global Acinetobacter Pneumonia Therapeutics Market, Key Players
- Pfizer Inc.
- Merck & Co., Inc.
- GlaxoSmithKline plc (GSK)
- AstraZeneca plc
- Novartis AG
- Johnson & Johnson
- Sanofi S.A.
- Bayer AG
- Basilea Pharmaceutica
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Acinetobacter Pneumonia Therapeutics Market, By Drug Class
- Global Acinetobacter Pneumonia Therapeutics Market, By Route of Administration
- Global Acinetobacter Pneumonia Therapeutics Market, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Rising prevalence of Acinetobacter pneumonia infections
- Increasing research & development activities
- Growing healthcare expenditure
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Service offering Portfolio
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Pipeline Analysis
4. Global Acinetobacter Pneumonia Therapeutics Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Acinetobacter Pneumonia Therapeutics Market, By Drug Class, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Cephalosporins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
- Carbapenems
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
- Aminoglycosides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
- Polymyxins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
6. Global Acinetobacter Pneumonia Therapeutics Market, By Route of Administration, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
7. Global Acinetobacter Pneumonia Therapeutics Market, By Region, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Region, 2019 - 2030
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2018-2030,(US$ Mn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co., Inc.
- GlaxoSmithKline plc (GSK)
- AstraZeneca plc
- Novartis AG
- Johnson & Johnson
- Sanofi S.A.
- Bayer AG
- Basilea Pharmaceutica
- Analyst Views
9. Section
- Research Methodology
- About us
